EPGNY

Epigenomics (QX) Share Price

12.39
0.00 (0.0%)
12.39
Best deals to access real time data!
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Small Cap Pro
Monthly Subscription
for only
$49.05
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
VAT not included
Company Name Stock Ticker Symbol Market Type
Epigenomics AG (QX) EPGNY OTCMarkets Depository Receipt
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 12.39 16:24:56
Open Price Low Price High Price Close Price Prev Close
12.39 12.39
Bid Price Ask Price Spread News
0.01 13.29 13.28 - -
Trades Volume Avg Volume 52 Week Range
1 1 - 0.225 - 0.26
Last Trade Time Type Quantity Stock Price Currency
09:31:16 1  11.63 USD

Epigenomics (QX) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 72.99M 5.89M -  -  - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - 0.00% - -

more financials information »

News Epigenomics (QX)

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

EPGNY Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Epigenomics is a molecular diagnostics company focused on blood-based detection of cancers using its proprietary DNA methylation biomarker technology. The company develops and commercializes diagnostic products across multiple cancer indications with high medical need. Epigenomics' lead product, Epi proColon, is a blood-based screening test for the detection of colorectal cancer. Epi proColon has received approval from the U.S. Food and Drug Administration (FDA) and is currently marketed in the United States, Europe, and China and selected other countries. Epi proLung, a test for lung cancer detection, and HCCBloodTest, a test for liver cancer, have received CE mark in Europe. For more information, visit www.epigenomics.com.


Your Recent History
USOTC
EPGNY
Epigenomic..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.